Introduction {#Sec1}
============

Emerging viruses with a high rate of genetic drift cause setbacks in the global scientific effort to develop fast and accurate diagnostic detection methods. A novel virus, SARS-associated coronavirus (SARS-CoV), which spread throughout the world in 2003, was quickly characterised \[[@CR13], [@CR21]\] and linked to severe acute respiratory syndrome (SARS) \[[@CR2], [@CR11], [@CR15]\]. Human coronaviruses are confined mainly to the upper respiratory tract, causing simple illnesses, whereas in animals, they have been associated with severe diseases \[[@CR16]\]. There is still an ongoing possibility of SARS-CoV re-emergence, since evidence suggests that it arose from an animal coronavirus \[[@CR5], [@CR25]\]. Poor clinical definition and lack of known prevention methods and treatments \[[@CR10], [@CR22]\] mean that early diagnosis is crucial. There has been a huge effort to develop diagnostics \[[@CR1], [@CR9], [@CR12], [@CR17], [@CR18], [@CR26], [@CR27]\], nevertheless, molecular detection tests suffer from speed and sensitivity limitations and are not standardised \[[@CR14], [@CR22]\]. Accurate and prompt detection of the virus is, therefore, a priority.

Current molecular assays fail to consider the intrinsically polymorphic nature of coronaviruses, as seen in the pathogenic SARS-CoV Tor2 and Urbani strains, and the possibility of continuous introductions of genetically non-identical strains into human populations. This study aimed to develop a real-time RT-PCR assay using mismatch-tolerant molecular beacons \[[@CR6], [@CR7], [@CR24]\] to detect SARS-CoV and to distinguish between pathogenic and non-pathogenic strains. The assay incorporates four beacons, targeting the *S*, *E*, *M* and *N* genes in addition to an internal positive control (IPC), and it was validated using clinical samples.

Materials and methods {#Sec2}
=====================

Molecular beacon and primer design {#Sec3}
----------------------------------

Primers and molecular beacons were designed *de novo* for this study (Table [1](#Tab1){ref-type="table"}). Small regions (95-107 nucleotides long) of the SARS-CoV *S*, *E*, *M* and *N* genes were targeted for detection (Fig. [1](#Fig1){ref-type="fig"}). The oligonucleotide design was based on multiple alignments of sequences of these genes available in the GenBank database (<http://www.ncbi.nlm.nih.gov/Genbank>) and thermodynamic compatibility. Careful choice of beacons and primers by use of the Integrated DNA Technologies (<http://eu.idtdna.com>) dimerisation tool ensured the avoidance of potentially hazardous primer-primer or molecular beacon-primer dimerisation and the thermodynamic compatibility of the beacons with their application in a five-amplicon multiplex assay. The molecular beacons, target oligonucleotides and primers were synthesised at MWG-Biotech AG Ltd (Ebersberg, Germany). To facilitate formation of stem structures, the ends of each molecular beacon were designed to have a high GC content and to be complementary to each other. All beacons were labelled with DABCYL, (4′-(4′-dimethylaminophenylazo) benzoic acid) at the 3' end and TET (tetrachloro-6′-carbofluorescein) at the 5' end, except MBIPC, the IPC beacon, which was labelled with FAM (fluorescein). To form the loop element, each beacon was designed to contain a 24-26-nucleotide-long probe sequence complementary to part of the gene fragment to be amplified. The beacons were designed to form long, stable hybrids, giving them the ability to be mismatch-tolerant, meaning that the beacons can still detect their target amplicons despite any polymorphic substitutions arising as a consequence of genetic drift of the virus or viral recombination. The GC content of the beacon was kept high to ensure that, under the PCR cycling conditions, the molecular beacon would remain in a closed conformation in the absence of its target. In order to identify the best target sequences within each viral gene that would discriminate the SARS-Urbani and SARS-Tor2 strains from other non-pathogenic human and animal coronavirus strains, multiple sequence alignments of available coronavirus gene sequences deposited in GenBank were carried out (Fig. [2](#Fig2){ref-type="fig"}). DNA sequences of SARS-CoV genes of SARS-Urbani (GenBank accession number AY278741) and SARS-Tor2 (AY274119) were compared with those from reference viruses representing each species in the three known groups of coronaviruses. Reference sequences from group 1 (G1) included human coronavirus 229E (HCoV-229E), AF304460; porcine epidemic diarrhea virus (PEDV), AF353511; transmissible gastroenteritis virus (TGEV), AJ271965; canine coronavirus (CCoV), D13096; feline coronavirus (FCoV), AY204704; porcine respiratory coronavirus (PRCoV), Z24675. Those from group 2 (G2) were bovine coronavirus (BCoV), AF220295; murine hepatitis virus (MHV), AF201929; human coronavirus OC43 (HCoV-OC43), M76373; porcine hemagglutinating encephalomyelitis virus (HEV), AY078417; rat coronavirus (RtCoV), AF207551; and the references virus for group 3 (G3) was infectious bronchitis virus (IBV), M95169. Sequence alignments were performed with ClustalW \[[@CR23]\] to identify genomic regions with the highest genetic distance between SARS-CoV and other coronavirus strains, with special emphasis on probe-target sequences that encompass gaps or deletions in the SARS-CoV genome. Like the probe sequences, primer selection was also based on the ability for amplification of the SARS-CoV targets that would form primer-target and probe-target hybrids with a theoretical melting temperature that would maximize the ability of the primer to bind to the target even if nucleotide substitutions are present to achieve mismatch tolerance. Finally, primer sequences were selected that enable the amplicons formed to be approximately the same length, about 100 nucleotides.Table 1Oligonucleotide PCR primers, target amplicons and molecular beacons used in the real-time PCR assayDesignation^a^Target geneSequencePosition^b^Amplicon length (nt)Accession numberPCR primers 22071 (F)*S*CTCTATGTTTATAAGGGCTATCAACC22071--2209695AY274119 22165 (R)*S*CCAAGAGGCAACTTAAAAATAGGTTTC22139--22165AY274119 26133 (F)*E*CGGAAGAAACAGGTACGTTAATAG26133--2615695AY274119 26227 (R)*E*AAGCGCAGTAAGGATGGCTA26208--26227AY274119 26545 (F)*M*CTTGTTTTCCTCTGGCTCTTG26545--26565107AY274119 26651 (R)*M*CAAGCCATTGCAATCGCAATC26631--26651AY274119 28398 (F)*N*ACGAGTTCGTGGTGGTGAC28398--2841695AY274119 28492 (R)*N*CGTAGGGAAGTGAAGCTTC28474--28492AY274119Target amplicons TgeneS*S*CTCTATGTTTATAAGGGCTATCAACCTATAGATGTAGTTCGTGATCTACCTTCT GGTTTTAACACTTTGAAACCTATTTTTAAGTTGCCTCTTGG22071--2216595AY274119 TgeneE*E*CGGAAGAAACAGGTACGTTAATAGTTAATAGCGTACTTCTTTTTCTTGCTTTCG TGGTATTCTTGCTAGTCACACTAGCCATCCTTACTGCGCTT26133--2622795AY274119 TgeneM*M*CTTGTTTTCCTCTGGCTCTTGTGGCCAGTAACACTTGCTTGTTTTGTGCTTGCTG CTGTCTACAGAATTAATTGGGTGACTGGCGGGATTGCGATTGCAATGGCTTG26545--26651107AY274119 TgeneN*N*ACGAGTTCGTGGTGGTGACGGCAAAATGAAAGAGCTCAGCCCCAGATGGTACTTCTATTACCTAGGAACTGGCCCAGAAGCTTCACTTCCCTACG28398--2849295AY274119 TIPCN/ACTCTATGTTTATAAGGGCTATCAACCTATAGATGCTGCTGTCTACAGCCCCAG ATGGTAGTATTCTTGCTAGTCACACTAGCCATCCTTACTGCGCTTN/A98N/AMolecular beacons^c^ MBgeneS*S*TET-[CCCACG]{.ul}CCAGAAGGTAGATCACGAACTACA[CGTGGG]{.ul} -DABCYL22104--22127AY274119 MBgeneE*E*TET-[CCTCCG]{.ul}CACGAAAGCAAGAAAAAGAAGTACGC[CGGAGG]{.ul}-DABCYL26163--26188AY274119 MBgeneM*M*TET-[CCTCCG]{.ul}ACCCAATTAATTCTGTAGACAGCAGC[CGGAGG]{.ul}-DABCYL26593--26627AY274119 MBgeneN*N*TET-[CCTCCG]{.ul}TACCATCTGGGGCTGAGCTCTTTCAT[CGGAGG]{.ul}-DABCYL28423--28449AY274119 MBIACN/AFAM-[GCCCACG]{.ul}TACCATCTGGGGCTGTAGACAGCAGC[CGTGGGC]{.ul}-DABCYLN/AN/A^a^PCR primer, oligonucleotide and molecular beacon names are as they appear in the text; The orientation of the PCR primer is indicated in parentheses: F, forward; R, reverse^b^Positions correspond to the appropriate GenBank sequences. In the case of molecular beacons, the positions correspond to the target recognition sequences of the molecular beacon probe except in the case of MBgeneM and MBgeneN, where the molecular beacon arms also possess bases that hybridize to complementary bases in the target sequence, as explained in [Materials and methods](#Sec2){ref-type="sec"} and [Discussion](#Sec13){ref-type="sec"}^c^Underlined regions denote the sequences that form the stem of the molecular beacon; FAM, fluorescein; TET, tetrachloro-6′-carbofluorescein; DABCYL, 4′-(4′-dimethylaminophenylazo) benzoic acid Fig. 1Assay design. Schematic representation of the SARS-associated coronavirus (SARS-CoV) genome highlighting the main protein-encoding genes, which are also targeted in this assay (**A**), and magnified to indicate the start and end locations of these genes and the known open reading frames using nucleotide positions (**B**). Further magnification of the target genes (**C**) shows the amplicons of each of the four genes (*S, E, M* and *N*) incorporated in the assay. Target sequences of the amplicons are shown in boxes, whereas primers and molecular beacons are shown in bold. Numbers indicate the nucleotide positions of the start and end locations of the target amplicon that correspond to forward primer, probe and reverse primer, using the SARS-Tor2 strain (GenBank accession no. AY274119) Fig. 2Sequence alignments of the target genes. DNA sequence alignments of the gene regions targeted in the real-time PCR assay to compare SARS-CoV-specific genes from SARS-Tor2 and SARS-Urbani strains to those of other non-pathogenic human and animal reference strains representing each species in the three known groups of coronaviruses. Group 1 (G1): human coronavirus 229E (HCoV--229E); porcine epidemic diarrhoea virus (PEDV); transmissible gastroenteritis virus (TGEV); canine coronavirus (CCoV); feline coronavirus (FCoV); porcine respiratory coronavirus (PRCoV). Group 2 (G2): bovine coronavirus (BCoV); murine hepatitis virus (MHV); human coronavirus OC43 (HCoV--OC43); porcine hemagglutinating encephalomyelitis virus (HEV); rat coronavirus (RtCoV). Group 3 (G3): infectious bronchitis virus (IBV). GenBank accession numbers are AY278741, AY274119, AF304460, AF353511, AJ271965, D13096, AY204704, Z24675, AF220295, AF201929, M76373, AY078417, AF207551 and M95169, respectively. Optimal target sequences that discriminate the SARS-associated pathogenic strains from the rest were identified. Numbers indicate the nucleotide position according to the SARS-Tor2 genome (GenBank accession no. AY274119). The primers and molecular beacon and their target sequences are highlighted in the alignments

Internal positive control {#Sec4}
-------------------------

A synthetic oligonucleotide was designed to be amplified by the forward *S* gene and reverse *E* gene primers (Table [1](#Tab1){ref-type="table"}) and used as an internal positive control (IPC) during amplification.

Thermal profiles of molecular beacons {#Sec5}
-------------------------------------

The thermodynamic characteristics of the molecular beacons were assessed by melting curve analyses performed in a 7700 Prism Spectrofluorometric Thermal Cycler (Applied Biosystems, Foster City, CA, USA) and validated using the 7900 HT Fast Real-Time PCR System (Applied Biosystems). Different concentrations of beacons were used to find one at which fluorescence was neither too low nor saturating. The 25-μl reaction consisted of 1X Platinum ® PCR Supermix (Invitrogen), 1 μl of the beacon in various concentrations, with or without 100 pmol of a single-stranded complementary target. The cycling parameters were as follows: 2 min at 95°C, followed by 50 cycles of data collection for 30 s and a second step for 10 s, starting at 80°C and decreasing by 1°C per cycle. Fluorescence was measured at 490 nm and recorded at each cycle.

RNA standards {#Sec6}
-------------

RNA transcripts corresponding to all targets were prepared by *in vitro* transcription using a MEGAscript T7 transcription kit (Ambion, Houston, TX) according to the manufacturer's instructions. DNA templates were generated by PCR using forward primers (Table [1](#Tab1){ref-type="table"}) with the bacteriophage T7 RNA polymerase promoter recognition sequence (TAATACGACTCACTATAGG) incorporated at their 5' end and reverse primers integrating the gene-specific reverse transcriptase primer-binding site at their 3' end (22165-RT, 5'-[AGGCTGTAAGAA]{.ul}CCAAGAGGCAACTTAAAAATAGGTTTC-3'; 26227-RT, 5'-[TATTGCAGCAGTAC]{.ul}AAGCGCAGTAAGGATGGCTA-3'; 26651-RT, 5'-[AAGCAACGAAGTAG]{.ul}CAAGCCATTGCAATCGCAATC-3'; or 28492-RT, 5'-[GCCTTCTTTGTTAG]{.ul}CGTAG GGAAGTGAAGCTTC-3'; the gene-specific reverse transcriptase binding sites are underlined).

The PCR reaction contained 1X PCR buffer (QIAGEN, Mississauga, Canada), 0.5 mmol/L dNTPs (Gibco BRL), 0.4 μmol/L of each primer and 2.5 U of HotStar*Taq* DNA polymerase (QIAGEN). The amplification conditions were as follows: 95°C for 15 min, 40 cycles of 94°C for 30 s, 55°C for 30 s and 72°C for 80 s, followed by 72°C for 5 min. The eluted RNA transcripts were purified and measured with a UV spectrophotometer (NanoDrop Technologies, USA).

Clinical samples {#Sec7}
----------------

The samples included in this study were collected from patients who met the CDC/WHO case definition of probable SARS in Toronto, Canada, in 2003. Fifty post-mortem tissue samples (Table [2](#Tab2){ref-type="table"}) were collected from 17 patients who died of probable SARS. Twenty-one post-mortem and two pre-mortem tissue samples from eight individuals who died from causes other than SARS during the outbreak were included as controls. Samples collected at the time of autopsy were snap-frozen in ethanol and dry ice and stored at −70°C. Samples were coded and processed independently. This study was approved by the research ethics boards of the Mount Sinai Hospital and the University Health Network, Toronto, and the Chief Coroner's Office of Ontario, Canada.Table 2Real-time RT-PCR results obtaind with specimens from patients displaying SARS-coronavirus dissemination to multiple organsPatient^a^Type of specimen analyzed^b^RT-PCR result^c^*SEMN*IPC1Large intestine, small intestine, left lower lobe of lung+++++2Right upper lobe of lung+++++3Left lower lobe of lung+++++4Right upper lobe of lung+++++5Large intestine, lung+++++6Right upper lobe of lung+++++7Lung+++++8Large intestine, small intestine+++++9Lung+++++10Right lower lobe of lung+++++11Left lower lobe of lung+++++12Large intestine, small intestine+++++13Large intestine, small intestine+++++14Small intestine+++++15Large intestine+++++16Large intestine+++++17Small intestine+++++18Heart, large intestine, small intestine, liver, skeletal muscle, right lung, spleen−−−−+19Heart, small intestine−−−−+20Heart, small intestine, skeletal muscle−−−−+21Large intestine−−−−+22Heart−−−−+23Liver−−−−+24Bronchial lavage−−−−+25Bronchial lavage−−−−+^a^These patients include 17 cases whose death was attributed to SARS (patient numbers 1-17) and 8 controls who died of causes other than SARS during the same period (patient numbers 18-25) as described in [Materials and methods](#Sec2){ref-type="sec"}^b^These specimens were obtained postmortem at the time of autopsy with the exception of the two bronchial lavage samples, which were collected pre-mortem^c^A detectable real-time PCR amplification signal is denoted by the symbol (+) which indicates consistent C~T~ values ≤ 45 for all four SARS-CoV genes assayed in this experiment. An undetectable signal (C~T~ values \>45) is denoted by (−) and indicates the absence of template cDNA

For RT-PCR preparation, 30 mg of each sample was thawed and homogenized in 600 μl RLT lysis buffer (QIAGEN) using disposable tissue grinders (Kendall Precision^TM^, Mansfield, USA). The homogenate was passed through QIAshredder columns (QIAGEN) prior to RNA isolation using an RNeasy Mini Kit (QIAGEN).

Reverse transcription and real-time RT-PCR {#Sec8}
------------------------------------------

Samples were analysed in duplicate in duplex and multiplex RT-PCR reactions. For reverse transcription, 2 μl of RNA served as a template in a reaction with 20 pmol IPC RT primer (E-RT; 5'-TATTGCAGCAGTAC-3') and 20 pmol of one of the other RT primers (S-RT; 5'-AGGCTGTAAGAA-3', E-RT, M-RT; 5'-AAGCAACGAA GTAG-3' or N-RT; 5'-GCCTTCTTTGTTAG-3'; the same RT primer, E-RT, was used for both gene *E* and IPC), using an Omniscript Reverse Transcription Kit (Qiagen, Hilden, Germany). Reactions were incubated at 37°C for 60 min followed by inactivation at 95°C for 5 min.

Real-time RT-PCR was carried out on a LightCycler real-time PCR platform (Roche Diagnostics, Laval, Canada) using a Platinum® *Taq* Polymerase PCR Kit (Invitrogen). Each 20-μl reaction contained 2 μl template cDNA, 10 pmol each of the beacon, the MBIPC and the primers, 87.5 pmol MgCl~2~ and 1X PCR buffer. Cycling conditions were 95°C for 30 s, 40 cycles of 95°C for 20 s, 45°C for 20 s (data collection) and 72°C for 20 s. Non-template controls were also run. In the multiplex protocol, the same cycling conditions and reagents were applied, and the beacons and primers (Table [1](#Tab1){ref-type="table"}) of all four SARS-CoV genes (10 pmol each) were added in each reaction.

A similar analysis was performed on the synthetic RNA standards. Reverse transcription was carried out as described above. Duplex real-time RT-PCR was carried out using a 7700 Prism spectrofluorometric thermal cycler (Applied Biosystems) and confirmed on a 7900 HT Fast Real-Time PCR System (Applied Biosystems). Each 25-μl duplex PCR reaction contained 5 μl cDNA, 1X Platinum® Quantitative Supermix-UDG (Invitrogen), 10 pmol MBIPC, 10 pmol molecular beacon (Table [1](#Tab1){ref-type="table"}) and 20 pmol each of the target and IPC primers (Table [1](#Tab1){ref-type="table"}). Initial denaturation was carried out at 95°C for 10 min, followed by 50 cycles at 95°C for 15 s, 45°C for 30 s (data collection step) and 72°C for 30 s.

Statistical evaluation of the real-time PCR assay {#Sec9}
-------------------------------------------------

To evaluate the specificity and target detection ability of the assay, 95% confidence intervals were calculated using a Wilson score interval.

Results {#Sec10}
=======

Thermal denaturation characteristics of molecular beacons {#Sec11}
---------------------------------------------------------

Normalised fluorescence signals for beacon and beacon-target hybrids were plotted against temperature to give thermal denaturation profiles (Fig. [3](#Fig3){ref-type="fig"}) and to determine the optimal hybridisation temperature between the beacon and its target. The beacons alone exhibited a melting temperature above 60°C. In the 31-55°C temperature range, the probe-target hybrids elicited significantly stronger fluorescence than the probe alone, allowing clear detection. A temperature of 45°C was chosen as optimal for the real-time PCR reactions. The optimal concentration for all beacons was found to be 10 pmol/μl.Fig. 3Thermal denaturation profiles of the molecular beacons. Thermal denaturation profiles of the molecular beacons used in this study as established by melting curve analysis (described in [Materials and methods](#Sec2){ref-type="sec"}). The figure shows normalised fluorescence thermal transitions of molecular beacons (bottom part of plot) and beacon-target complexes (top part of plot)

Real-time RT-PCR evaluation {#Sec12}
---------------------------

The assay was tested on synthetic RNA standards and clinical samples (Table [2](#Tab2){ref-type="table"}). All samples were investigated in duplicate with duplex and multiplex assays to detect the IPC and the *S*, *E*, *M* and *N* genes. Positive results had C~T~ values of 5-15 for lung tissue and 10-25 for intestinal tissue. All 50 specimens from the 17 SARS-CoV-infected cases were found positive for the four targets, indicating a detection ability of 100% (95%CI = 81.6-100%). The specificity was also 100% (95%CI = 67.6-100%), since all 21 control specimens were negative (C~T~ \> 45). Non-template controls were included in all assays and exhibited undetectable amplification (C~T~ \> 45). Detection of both the IPC and the SARS-CoV-specific genes were clear in all SARS-CoV-infected samples, whereas only the IPC amplification was detected in the controls.

The results show that the real-time RT-PCR accurately detects SARS-CoV RNA and is both accurate and specific enough to distinguish all SARS-CoV-infected samples from control samples. The assay gives the same results on any of three different PCR platforms used (Lightcycler, ABI7700 and ABI7900).

The technology described in this study is part of US Patent No. 7,709,188 B2, issued 4 May 2010.

Discussion {#Sec13}
==========

A future re-emergence of SARS-CoV is possible, since viruses are difficult to eradicate and are able to survive in intermediate hosts. A fast, accurate detection assay for routine diagnostic tests may be crucial if therapies are to be applied efficiently and effectively. Furthermore, such assays may be adapted for other mutating infectious agents, which also pose a public health hazard.

Despite being a coronavirus by morphology \[[@CR11]\], SARS-CoV strains Tor2 \[[@CR13]\] and Urbani \[[@CR21]\] have a distant relationship to other known coronaviruses. Phylogenetic analysis revealed regions of very low similarity between the SARS-CoV strains and other coronaviruses. These genetically distant regions have been used here for the design of primers and molecular beacons (Figure [2](#Fig2){ref-type="fig"}). The lack of a significant phylogenetic relationship between SARS-CoV and other coronaviruses in the S, E, M and N proteins has been reported previously \[[@CR19]\]. The same study also demonstrated no recombinant N or S protein in the SARS-CoV lineage. This and the fact that they are transcribed in large quantities were reasons for choosing the *N* and *S* genes as targets.

The existing SARS detection methodology fails to consider the polymorphic nature of coronaviruses and to account for the possibility of introductions of genetically non-identical strains into human populations. The present assay tackles this first by using multiple genetic sequences as targets. The reason for using four different molecular beacons, each targeting a different gene, is to minimise the likelihood of not detecting SARS-CoV due to continuous evolutionary changes in the virus. Also, by simultaneously detecting four targets with multiplex single-fluorophore detection, detection sensitivity is enhanced compared to the detection of just one target. SARS-CoV viral load is extremely low at disease onset, raising a major challenge for early detection \[[@CR20]\]. Secondly, mismatch-tolerant molecular beacons have been designed to achieve a compromise between specificity and mismatch tolerance. Traditionally, targets are chosen to be perfectly complementary to the probes, making binding extremely specific \[[@CR24]\]. Mismatch-tolerant beacons form longer probe-target hybrids, allowing the duplex to contain mismatched base-pairs \[[@CR3]\]. Thus, the beacons designed here bind only to gene regions of the selected pathogenic strains and at the same time could tolerate unpredicted base substitutions.

The assay exhibited target detection ability and specificity of 100%. The detection limit of the assay was also investigated by constructing standard curves using *in vitro* RNA transcripts, which were linear over a 6-log range of target concentrations, and the lower limit of detection was 5 copies per reaction (data not shown). All SARS-CoV-infected clinical samples were positive, and all control samples were negative (Table [2](#Tab2){ref-type="table"}). Low C~T~ values were observed in lung samples where the SARS-CoV viral load has been reported to be highest amongst human organs \[[@CR4]\]. Furthermore, these results support reports of viral dissemination in the lobes of the lung \[[@CR14]\] and multiorgan viral dissemination \[[@CR4], [@CR8]\]. Potential false negative results were avoided by including an internal positive control.

This is the first report of a real-time RT-PCR SARS-CoV detection assay with molecular beacons that can tolerate mutations attributed to genetic drift and recombination, can distinguish between SARS-CoV and non-pathogenic coronavirus strains and includes an internal positive control. This assay provides a fast and simple way to detect SARS-CoV in diagnostic tests, and, importantly, provides a template for fast molecular detection assays for emerging mutating pathogens.
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